BioLineRx (BLRX) Non-Current Assets (2011 - 2025)

BioLineRx's Non-Current Assets history runs 15 years deep, the most recent figure standing at $17.2 million for Q4 2025.

• On a quarterly basis, Non-Current Assets rose 45.94% year-over-year to $17.2 million in Q4 2025; TTM through Dec 2025 was $17.2 million, a 45.94% increase from a year earlier, with the FY2025 full-year figure at $17.2 million, up 45.94% from the prior year.
• Non-Current Assets grew to $17.2 million in Q4 2025 per BLRX's latest filing, from $11.3 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $24.4 million in Q4 2022 and bottomed at $11.3 million in Q3 2025.
• The 5-year median for Non-Current Assets is $23.7 million (2022), against an average of $19.6 million.
• Across the five-year window, Non-Current Assets plunged 38.07% in 2024 and surged 45.94% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $24.0 million in 2021, then advanced by 1.65% to $24.4 million in 2022, then slumped by 31.34% to $16.7 million in 2023, then decreased by 29.51% to $11.8 million in 2024, then jumped by 45.94% to $17.2 million in 2025.
• Per Business Quant, the three latest BLRX Non-Current Assets figures stand at $17.2 million (Q4 2025), $11.3 million (Q3 2025), and $11.4 million (Q2 2025).